A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)
Sacituzumab govitecan (brand name: TRODELVY®) is a new treatment for certain types of advanced or metastatic breast cancer. One common type of breast cancer has at least 1 of 2 hormone receptors (HR positive) and does not have human epidermal growth factor 2 (HER2 negative). The HR and HER2 receptor...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
25 Jan 2024
|
| In: |
Future oncology
Year: 2024, Volume: 20, Issue: 11, Pages: 635-651 |
| ISSN: | 1744-8301 |
| DOI: | 10.2217/fon-2023-0845 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.2217/fon-2023-0845
|
| Author Notes: | Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Patricia A Spears, Sara M Tolaney |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1915501849 | ||
| 003 | DE-627 | ||
| 005 | 20250716224052.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-0845 |2 doi | |
| 035 | |a (DE-627)1915501849 | ||
| 035 | |a (DE-599)KXP1915501849 | ||
| 035 | |a (OCoLC)1528017456 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rugo, Hope S. |e VerfasserIn |0 (DE-588)1020214171 |0 (DE-627)691143218 |0 (DE-576)359869203 |4 aut | |
| 245 | 1 | 2 | |a A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative) |c Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Patricia A Spears, Sara M Tolaney |
| 264 | 1 | |c 25 Jan 2024 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.01.2025 | ||
| 520 | |a Sacituzumab govitecan (brand name: TRODELVY®) is a new treatment for certain types of advanced or metastatic breast cancer. One common type of breast cancer has at least 1 of 2 hormone receptors (HR positive) and does not have human epidermal growth factor 2 (HER2 negative). The HR and HER2 receptors are known to influence how severe a case of breast cancer is. Certain treatments will only work if a specific receptor is present on breast cancer cells. HR-positive/HER2-negative advanced or metastatic breast cancer can be treated with sacituzumab govitecan. This is a summary of the results of the TROPiCS-02 study. This study compared sacituzumab govitecan with standard chemotherapy in participants with HR-positive/HER2-negative advanced or metastatic breast cancer. The study showed that participants treated with sacituzumab govitecan lived significantly longer without their cancer getting worse than participants treated with chemotherapy. Participants also survived significantly longer and their tumors became significantly smaller in more participants treated with sacituzumab govitecan than with chemotherapy. In general, participants treated with sacituzumab govitecan were more likely to have side effects and had more severe side effects. These side effects included low levels of a type of white blood cell known as neutrophils and diarrhea. Oncologists (doctors that treat cancer) know of these side effects as they are common among people being treated for cancer. Doctors can control these side effects by following standard treatment guidelines and the package insert for sacituzumab govitecan. Participants treated with sacituzumab govitecan maintained their sense of well-being and ability to do daily activities (quality of life) longer than participants treated with chemotherapy. It also took longer for fatigue and other symptoms of cancer to worsen in participants treated with sacituzumab govitecan compared with chemotherapy. Sacituzumab govitecan is more effective than standard chemotherapies for people who have already received multiple treatments for HR-positive/ HER2-negative advanced breast cancer. The side effects from sacituzumab govitecan could generally be managed well by doctors. Although there were more side effects with sacituzumab govitecan than with chemotherapy, they were generally mild to moderate. A plain language summary of the TROPiCS-02 study shows that sacituzumab govitecan provided significant clinical benefit compared to chemotherapy with manageable side effects for people with pretreated HR-positive and HER2-negative metastatic breast cancer | ||
| 650 | 4 | |a antibody-drug conjugate | |
| 650 | 4 | |a breast | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a HER2-negative | |
| 650 | 4 | |a HR-positive | |
| 650 | 4 | |a lay summary | |
| 650 | 4 | |a plain language summary | |
| 650 | 4 | |a sacituzumab govitecan | |
| 650 | 4 | |a Trop-2 | |
| 700 | 1 | |a Bardia, Aditya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Cortes, Javier |e VerfasserIn |0 (DE-588)142653705 |0 (DE-627)638445590 |0 (DE-576)332633640 |4 aut | |
| 700 | 1 | |a Schmid, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spears, Patricia A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tolaney, Sara M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology |d London : Taylor & Francis, 2005 |g 20(2024), 11, Seite 635-651 |h Online-Ressource |w (DE-627)484405055 |w (DE-600)2184533-5 |w (DE-576)398100217 |x 1744-8301 |7 nnas |a A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative) |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:11 |g pages:635-651 |g extent:17 |a A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative) |
| 856 | 4 | 0 | |u https://doi.org/10.2217/fon-2023-0845 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250123 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1915501849 |e 4655447230 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 23.01.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"25 Jan 2024","dateIssuedKey":"2024"}],"title":[{"title_sort":"plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)","title":"A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)"}],"person":[{"display":"Rugo, Hope S.","family":"Rugo","given":"Hope S.","role":"aut"},{"role":"aut","family":"Bardia","given":"Aditya","display":"Bardia, Aditya"},{"role":"aut","display":"Marmé, Frederik","family":"Marmé","given":"Frederik"},{"role":"aut","display":"Cortes, Javier","given":"Javier","family":"Cortes"},{"display":"Schmid, Peter","family":"Schmid","given":"Peter","role":"aut"},{"role":"aut","given":"Patricia A.","family":"Spears","display":"Spears, Patricia A."},{"role":"aut","display":"Tolaney, Sara M.","given":"Sara M.","family":"Tolaney"}],"language":["eng"],"physDesc":[{"extent":"17 S."}],"name":{"displayForm":["Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Patricia A Spears, Sara M Tolaney"]},"relHost":[{"note":["Gesehen am 28.05.2024"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"2005","publisher":"Taylor & Francis ; Future Medicine Ltd","dateIssuedDisp":"2005-","publisherPlace":"London ; London"}],"pubHistory":["1.2005 -"],"title":[{"title":"Future oncology","title_sort":"Future oncology"}],"language":["eng"],"part":{"text":"20(2024), 11, Seite 635-651","issue":"11","year":"2024","extent":"17","pages":"635-651","volume":"20"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)Future oncology","id":{"eki":["484405055"],"issn":["1744-8301"],"zdb":["2184533-5"]},"recId":"484405055"}],"id":{"doi":["10.2217/fon-2023-0845"],"eki":["1915501849"]},"recId":"1915501849"} | ||
| SRT | |a RUGOHOPESBPLAINLANGU2520 | ||